Data for : Comparative Efficacy and Safety of Different Combination Therapies for Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis

This dataset contains the extracted data for the systematic review and network meta-analysis (NMA) entitled "Comparative Efficacy and Safety of Different Combination Therapies for Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis"The included files are:1.extracted_data_outcomes:The raw, study-level data extracted for all efficacy and safety outcomes used in the meta-analysis. This is the primary input data for all statistical analyses.2.Baseline Patient Characteristics:A summary table of the baseline characteristics of the included studies and their patient populations.3.Risk of bias assessment:The risk of bias assessment for each included randomized controlled trial, performed using the Cochrane Risk of Bias tool.The NMA compared the efficacy and safety of contemporary regimens including VRd, DRd, KRd, VCd, etc., for patients with newly diagnosed multiple myeloma (NDMM). Outcomes include progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and key adverse events (AEs).For a detailed explanation of variables, please refer to the accompanying README file.

本数据集包含题为《初诊多发性骨髓瘤不同联合疗法的比较疗效与安全性：一项网络meta分析（network meta-analysis, NMA）》的系统评价与网络meta分析所提取的数据。
纳入文件如下：
1. extracted_data_outcomes：为荟萃分析所用全部疗效与安全性结局提取的原始研究级数据，是所有统计分析的核心输入数据。
2. Baseline Patient Characteristics：纳入研究及其患者人群的基线特征汇总表。
3. Risk of bias assessment：采用Cochrane偏倚风险工具对每一项纳入的随机对照试验开展的偏倚风险评估。
本网络meta分析对比了当代治疗方案（包括VRd、DRd、KRd、VCd等）用于初诊多发性骨髓瘤（newly diagnosed multiple myeloma, NDMM）患者的疗效与安全性。分析结局涵盖无进展生存期（progression-free survival, PFS）、总生存期（overall survival, OS）、总缓解率（overall response rate, ORR）以及关键不良事件（adverse events, AEs）。
有关变量的详细说明，请参阅随附的README文件。